Beyond DNA: Exploring the Untapped Potential of the Human Genetics Market

Human Genetics Market

The global human genetics market is expected to have a market value of USD 65.18 Billion by 2032.

The Human Genetics Market is witnessing a transformative era driven by advancements in genomics and human molecular genetics. Genomics, the study of an organism's complete set of DNA, is at the forefront of this revolution, enabling researchers and healthcare professionals to delve into the intricacies of human genetic information. As a result, the market is experiencing unprecedented growth with a focus on personalized medicine, genetic testing, and targeted therapies.

Human molecular genetics, a subfield of genetics that explores the molecular mechanisms underlying genetic traits and disorders, plays a pivotal role in understanding the genetic basis of various diseases. The integration of genomics and human molecular genetics has paved the way for breakthroughs in diagnostics, treatment, and drug development.

The demand for genetic testing services has surged, driven by the increasing awareness of personalized healthcare and the potential to uncover individualized treatment options. The Human Genetics Market is characterized by collaborations between biotechnology companies, research institutions, and healthcare providers to leverage genomic data for precision medicine.

Top of Form

Major Key Players:

MRFR recognizes Human Genetics Market Players are— Myriad Genetics (US), Synlab Group (Germany), Eurofins Megalab S.A (Spain), Biomarker Technology (US), Echevarne Laboratory (Spain), Elabscience Biotechnology Inc (US), NIMGenetics (Spain), Sistemas Genómicos (Spain), FullGenomics (Spain), GENinCode (UK), Atrys Health (Spain), Genyca (Spain), Igenomix (India), Genologica (Spain), Bode Technology Group Inc (US).

Segmentation

The global human genetics market is segmented into application, end user and region. The application segment is further segmented into wellness & E-commerce, preventive medicine, diagnostic & treatment. The diagnostic & treatment segment is further sub-segmented into oncology, cardiology, assisted reproduction, neurology, gynecology, others. 

The neurology segment is further sub-segmented into neuropediatric, others. The test segment is further segmented into NIPT, carrier testing, pharmacogenomic testing, karyotype testing, thrombophilia testing, septin 9 biomarker testing, NGS, others. The NGS segment is further sub-segmented into oncology, cardiology, others.

Regional Analysis

The global human molecular genetics market, based on region, has been divided into US, Canada, UK, Germany, Spain, Japan, others.

The human genetics market in the US benefits from a high healthcare expenditure, increasing demand for genetic testing by the population, and high public awareness regarding early detection of diseases and preventive care. Moreover, the availability of reimbursements in the US for genetic tests further improves market growth in the country. For instance, in October 2019, United HealthCare Services, Inc. (US), the largest health insurance company in the US, started providing insurance coverage for multi-panel genetic testing. According to the National Institutes of Health (NIH), in July 2023, over 77,000 genetic tests are currently used in the US, and more are under development.

Public-funded genetic testing in Canada is highly restricted and is only available to a select few who fall into certain criteria, such as a family history of cancer and early onset of cancer. Additionally, people in Canada who want their genetic testing done can opt for direct-to-consumer genetic tests such as color and invitae. Results from these tests can then be consulted with genetic counselors. Furthermore, there are human genetics programs to test patients with genetic disorders across Canada. For instance, the Hereditary Cancer Program is based in British Columbia, Canada, conducting genetic counseling and tests to detect hereditary cancer.

Clinically directed genetic testing has been available for several decades in the NHS for predictive testing for family members and molecular genetic investigation of a clinical presentation. Genomic health data in the UK is generated in three major areas, including large-scale research programs, the healthcare system, and purchasing of direct-to-consumer genetic testing. Moreover, the rise in the number of initiatives undertaken by the public as well as private organizations is further aiding the market growth. For instance, in April 2023, GEN inCode UK Limited announced its collaboration with Royal Brompton and Harefield hospitals (RB&H) for providing cardiovascular disease clinical genetic testing and reporting. In August 2023, DnaNudge announced the completion of its Series A investment round of USD 60 million led by Ventura Capital

The rising prevalence of genetic disorders, cancer, increasing awareness and acceptance regarding personalized medicines, and growing focus on R&D activities contribute to the country's growth. As per the data published by Global Cancer Observatory in March 2023, cancer accounted for 628,516 new cases and 252,065 deaths in Germany in 2023. In addition, the government is implementing a number of favorable and collaborative policies to incorporate genetic testing into the healthcare system and provide insurance reimbursements to citizens, which, in turn, is driving the market growth.

For More Information, Please Visit @ Market Research Future

Comments

Post a Comment

Popular posts from this blog

Precision Medicine: Tailoring Healthcare for Individual Needs

  In recent years, the healthcare industry has witnessed a paradigm shift with the advent of personalized medicine, a groundbreaking approach that tailors medical treatment to the individual characteristics of each patient. The US, at the forefront of medical innovation, has embraced personalized medicine, leveraging advancements in genomic medicine, precision medicine, and personalized healthcare to revolutionize patient care. Precision medicine , also known as personalized medicine, represents a departure from the traditional one-size-fits-all approach to healthcare. Instead of treating patients based on generalized guidelines, precision medicine takes into account individual genetic makeup, lifestyle factors, and environmental influences to devise targeted treatment plans. This approach has the potential to optimize therapeutic outcomes, minimize adverse reactions, and improve overall patient satisfaction. At the heart of personalized medicine lies  genomic medicine , a fie...
Read more

Streamlining Success: Biopharmaceutical Contract Manufacturing Solutions

  In the ever-evolving landscape of healthcare, contract manufacturing has emerged as a pivotal force driving innovation and efficiency across various sectors, including biopharmaceuticals and medical devices. The healthcare contract manufacturing market plays a crucial role in enabling companies to focus on core competencies while leveraging specialized expertise and resources for the production of pharmaceuticals, medical devices, and equipment. With a growing demand for advanced therapies and medical technologies, the market is witnessing robust growth, propelled by factors such as outsourcing strategies, technological advancements, and regulatory complexities. Biopharmaceutical Contract Manufacturing: Biopharmaceutical contract manufacturing  involves the outsourcing of the production of biologic drugs, vaccines, and other therapeutic proteins to specialized manufacturers. This segment of the healthcare contract manufacturing market has experienced significant expansion in...
Read more

Exploring Effective Treatments for Peripheral Neuropathy: A Comprehensive Guide

  Peripheral neuropathy, a condition affecting millions worldwide, has spurred significant advancements in its treatment landscape. From traditional therapies to cutting-edge interventions, the peripheral neuropathy treatment market continues to evolve rapidly. Let's delve into the dynamics, innovations, and future prospects of this burgeoning market. Peripheral neuropathy  is characterized by damage to the peripheral nerves, leading to symptoms like numbness, tingling, and pain, often affecting the hands and feet. Its causes are diverse, including diabetes, autoimmune disorders, infections, and exposure to toxins. As the prevalence of conditions such as diabetes rises globally, the demand for effective neuropathy treatment escalates. One of the primary drivers propelling the  peripheral neuropathy treatment  market forward is the increasing focus on innovation. Pharmaceutical companies and research institutions are investing heavily in developing novel therapeutics ...
Read more